What is the recommended intravenous ganciclovir dosing regimen?

Intravenous Ganciclovir Dosing Regimen

For CMV disease in children and adults, the standard intravenous ganciclovir induction dose is 5 mg/kg every 12 hours for 14-21 days, followed by maintenance therapy at 5 mg/kg once daily. 1

Dosing by Clinical Indication

Symptomatic Congenital CMV with Neurologic Involvement

• Ganciclovir 6 mg/kg IV every 12 hours for 6 weeks 1
• This higher dose (12 mg/kg/day total) has been shown to reduce viral load and improve hearing outcomes at 6-12 months, though approximately two-thirds of infants develop substantial neutropenia requiring dose modification in up to 48% of cases 1

Disseminated CMV Disease and Retinitis

• Induction: 5 mg/kg IV every 12 hours for 14-21 days 1
• May be increased to 7.5 mg/kg IV every 12 hours if needed 1
• Maintenance: 5 mg/kg IV once daily for 5-7 days per week for chronic suppression 1
• Infusion should be administered over 1-2 hours 1

CMV CNS Disease

• Ganciclovir 5 mg/kg IV every 12 hours PLUS foscarnet 60 mg/kg IV every 8 hours until symptoms improve, followed by chronic suppressive therapy 1
• This combination approach is recommended for severe neurologic involvement 1

Renal Dose Adjustments

Ganciclovir is substantially excreted by the kidney and requires dose modification based on creatinine clearance 2:

• CrCl ≥70 mL/min: Standard dosing (5 mg/kg every 12 hours)
• CrCl 50-69 mL/min: 2.5 mg/kg every 12 hours
• CrCl 25-49 mL/min: 2.5 mg/kg every 24 hours
• CrCl 10-24 mL/min: 1.25 mg/kg every 24 hours
• CrCl <10 mL/min: 1.25 mg/kg three times per week following hemodialysis 2

For patients on sustained low-efficiency dialysis (SLED), dosing patterns suggest 2.5 mg/kg/day for 8-hour SLED and 5 mg/kg/day for 24-hour SLED for prevention, though higher doses may be needed for treatment 3

Special Populations

Pediatric Considerations

• Recent pharmacokinetic data suggest that to achieve therapeutic exposure in children with normal renal function, doses should be increased to 15-20 mg/kg/day IV (divided every 12 hours), and up to 20-25 mg/kg/day IV in children with augmented renal clearance 4
• For prophylaxis, doses of 40 mg/kg/day oral valganciclovir may be needed 4

Preterm and Low Birthweight Infants

• Standard dosing of 6 mg/kg IV every 12 hours results in significantly higher drug concentrations (AUC approximately double that of term infants) and increased adverse effects in preterm infants 5
• Lower gestational age and weight correlate with higher drug exposure, suggesting dose reduction may be necessary, though optimal dosing remains undefined 5

Cystic Fibrosis Patients

• Patients with cystic fibrosis demonstrate approximately 50% higher bodyweight-normalized clearance and require maintenance doses increased by approximately 50% 6

Overweight/Obese Patients

• Both total body weight (TBW) and adjusted body weight (AdjBW) dosing strategies show similar rates of neutropenia and efficacy 7
• Either approach is acceptable, though TBW dosing is more commonly used 7

Critical Monitoring Requirements

Complete blood counts and platelet counts must be performed frequently due to high rates of myelosuppression 2:

• Neutropenia, anemia, and thrombocytopenia occur commonly 1
• Dose reduction or interruption may be necessary in up to 40% of patients due to hematologic toxicity 1
• Do not administer if absolute neutrophil count <500/µL or platelets <25,000/µL 2
• Granulocyte colony-stimulating factor can be used to ameliorate marrow suppression 1

Renal function monitoring is essential 2:

• Monitor serum creatinine or creatinine clearance carefully to allow for dosage adjustments 2
• Renal toxicity can occur and may require dose modification 1

Common Pitfalls and Caveats

• Ganciclovir resistance can emerge with long-term therapy, particularly in patients with primary CMV infection (donor positive/recipient negative) who have recurrence rates of 38% despite extended oral maintenance therapy 8
• Patients at highest risk for treatment failure include those with primary CMV infection (D+/R-), liver transplant recipients, and those with ganciclovir-resistant viral isolates 9, 8
• Combination therapy with foscarnet should be considered for sight-threatening retinitis or clinically resistant disease, though this is associated with substantial rates of adverse effects 1, 10
• The drug should be infused slowly over 1-2 hours to minimize toxicity; never give as an IV bolus 1
• Other toxicities include CNS effects, gastrointestinal dysfunction, thrombophlebitis, and elevated liver enzymes 1